Relationship between ABO Blood Group with Severity, Length of Hospitalization, and Mortality Rate of COVID-19 Patients
DOI:
https://doi.org/10.24293/ijcpml.v29i2.1988Keywords:
COVID-19 patients, ABO blood group, the severity of infection, the mortality rateAbstract
Previous research suggests that the ABO blood group may play a role in the immunopathogenesis of SARS-CoV-2 virus infection. The purpose of this study was to analyze the relationship between the ABO blood group and the severity, length of hospitalization, and mortality rate of COVID-19. A descriptive-analytic study with a cohort retrospective design, involving 257 research samples, was conducted. The statistical tests used in this research were the Kolmogorov-Smirnov test, the Chi-Square test, the Fisher Exact test, and the Kruskal-Wallis test. The test results were significant if the p-value <0.05. From the results of the study, it was found that the analysis of blood type with severity was not statistically significant (p> 0.05), as well as blood type with severity and length of treatment, there was no relationship between severity and length of stay in all blood groups (all with p>0.05) while for blood groups with severity and mortality, there was a relationship between blood type and high mortality in all blood groups (all with p<0.001). There was no relationship between blood type and severity of SARS-CoV-2 virus infection (all p>0.05). However, there was a significant relationship between criticality and high mortality in all blood groups (all with p<0.001). Pathophysiological mechanisms that explain the relationship between ABO blood type and SARS-CoV-2 infection, one of which is the presence of anti-A antibodies in group O individuals that bind to the A antigen in the viral envelope and block infection, in which blood group O has susceptibility to SARS virus infection. There is no relationship between ABO blood type and patient severity and length of stay, but there is a correlation between mortality and ABO blood type in COVID-19 patients.
Downloads
References
Stowell CP, Stowell SR. Biologic roles of the ABH and Lewis histo¬blood group antigens Part I: infection and immunity. Vox Sang. 2019;114(5):426–42.
Cismaru CA, Cismaru GL, Nabavi SF, Ghanei M, Burz CC, et al. Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID-19. J Cell Mol Med, 2021;25:591
Holodick NE, Rodriguez-Zhurbenko N, Hernandez AM. Defining natural anti- bodies. Front Immunol, 2017; 8:872.
Gampa A, Engen PA, Shobar R, Mutlu EA. Relationships between gastrointestinal microbiota and blood group antigens. Physiol Genomics, 2017; 49:473–83.
Shokri P, Golmohammadi S, Noori M, Nejadghaderi AS, Chahhoud K, Safitri S. The relationship between blood group and risk of infection with SARS-CoV-2 or development of severe outcomes: A review. April 2021. https://doi:10.1002/rmv.2247
6.Li J, Wang X, Chen J, Cai Y, Deng A, Yang M. Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. Br J Haematol, 2020; 190(1): 24-27.
Ray JG, Schull MJ, Vermeulen MJ, Park AL. Association between ABO and Rh blood groups and SARS-CoV-2 infection or severe COVID-19 illness. Ann Intern Med, 2021; 174(308): 315.
Liu N, Zhang T, Ma L, Zhang H, Wang H, et al. The impact of ABO blood group on COVID"19 infection risk and mortality: a systematic review and metaanalysis. Blood Rev, 2020;100785.
Kumara G, Nanchal R, Hererra M, Sakhuja A, Patel D, et al. Does ABO blood groups affect outcomes in hospitalized COVID-19 patients?. J Hematol 2021;10(3):98-105.
Goel R, Bloch EM, Pirenne F, Al-Riyami AZ, Crowe E, et al. ABO blood group and COVID-19: A review on behalf of the ISBT COVID-19 working group. The International Journal of Transfusion Medicine, 2021; 116(8): 849-861.
Zhao J, Yang Y, Huang HP, Li D, Gu D, et al. Relationship between the ABO blood group and the COVID-19 susceptibility. MedRxiv, 2020; 1-18.
Li J, Wang X, Chen J, Cai Yi, Deng A, Yang M. Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. Br J Haematol, 2020; 190: 24–7.
Breiman A, Ruven-Clouet N, Le Pendu J. Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2. PLoS Pathog, 2020; 16: e1008556.
Wu SC, Arthur CM, Wang J, Verkerke H, Josephson CD, et al. SARS-CoV-2 receptor binding domain preferentially recognizes blood group A. Blood Adv, 2020; 5(5): 1305-1309.
Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of sex, age, and comorbidities with mortality in covid-19 patients: A systematic review and meta-analysis. Intervirology, 2020; 64: 36-47.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel Coronavirus in Wuhan, China. Lancet, 2020; 395(10223): 497-506.
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of Coronavirus Disease (COVID-19) outbreak. J Autoimmun, 2020; 109: 102433.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
